Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

BACKGROUND: Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the management of hematologic toxicities. A previous pooled analysis from the PALOMA clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettl, Johannes, Im, Seock-Ah, Ro, Jungsil, Masuda, Norikazu, Colleoni, Marco, Schnell, Patrick, Bananis, Eustratios, Lu, Dongrui R., Cristofanilli, Massimo, Rugo, Hope S., Finn, Richard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068918/
https://www.ncbi.nlm.nih.gov/pubmed/32164785
http://dx.doi.org/10.1186/s13058-020-01263-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068918/
https://www.ncbi.nlm.nih.gov/pubmed/32164785
http://dx.doi.org/10.1186/s13058-020-01263-0

Ejemplares similares